UCB Entered into a Research Collaboration with Ariceum Therapeutics to Discover New Modalities for Immune-related Diseases and Cancer
- The collaboration’s goal is to discover peptide-radioisotope conjugates as potential therapeutics using technology platforms. The collaboration expands Ariceum's pipeline with 2 new programs at the discovery stage
- Ariceum will utilize UCB's expertise to discover novel synthetic macrocyclic peptides using its mRNA-display technology platform ExtremeDiversity. Ariceum's expertise in radiochemistry & labeling technology will be useful to UCB in enhancing its capacity & discovery of highly distinctive products for immune-related diseases
- Ariceum will use a special library to screen against oncology targets of interest. Ariceum's 177Lu-satoreotide tetraxetan is overexpressed in NETs & some aggressive cancers i.e., SCLC
Ref: PRnewswire | Image: UCB
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.